SA’s biggest pharmaceutical manufacturer, Aspen Pharmacare, has signed a preliminary agreement to produce the candidate Covid-19 vaccine being developed by US drugmaker Johnson & Johnson (J&J) at its Port Elizabeth site, it announced on Monday.

The news was cheered by shareholders, who boosted Aspen’s share price by up to 11.5% in intraday trading, its biggest daily gain since April 18. Its share price closed at R117.65, its highest since October 1...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now